UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

Commission File Number: 001-39619

 

NOTIFICATION OF LATE FILING

 

x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q
¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR  

 

For Period Ended: December 31, 2022

 

¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q
¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR
¨ Transition Report on Form 11-K  

 

For the Transition Period Ended:                                                                          

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:                                             

 

PART I

REGISTRANT INFORMATION

 

Full name of registrant Kiromic BioPharma, Inc.
Former name if applicable  
Address of principal executive office 7707 Fannin Street, Suite 140
City, state and zip code Houston, TX 77054

 

 

 

 

  

PART II

RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 

  (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
x  (b) The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

-1-

 

 

PART III

NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.

 

Kiromic BioPharma, Inc. (the “Company”) is working diligently to complete its annual report on Form 10-K for the fiscal year ended December 31, 2022 (the “2022 Form 10-K”); however, the Company continues to be in the process of completing its review and approval of the Form 10-K, including the financial statements and related disclosures, therefore the Company is unable to complete and file the 2022 Form 10-K by the required due date of March 31, 2023 without unreasonable effort and expense. The Company expects to file the 2022 Form 10-K no later than 15 calendar days after its originally prescribed due date.

 

PART IV

OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Jason Morris   832   968-4888
(Name)   (Area Code)   (Telephone Number)

  

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 

x Yes ¨ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 

¨ Yes x No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

-2-

 

 

Kiromic BioPharma, Inc.

(Name of Registrant as Specified in Charter)

 

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Dated: March 31, 2023   /s/ Pietro Bersani
  By: Pietro Bersani
  Title: CEO

 

-3-

 

Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Kiromic BioPharma Charts.
Kiromic BioPharma (NASDAQ:KRBP)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Kiromic BioPharma Charts.